S
Sinovation / 华科精准
Focuses on developing medical robot technology and intelligent medical product innovation
About Sinovation / 华科精准
Sinovation Medical Technology Co., Ltd., established in August 2015, is a medical technology firm focused on developing and manufacturing intelligent medical devices for neurosurgery. The company provides comprehensive technology and product solutions for treating brain diseases like epilepsy, Parkinson's disease, brain tumors, and cerebral hemorrhage. Its technology originates from two decades of research at Tsinghua University.
Read full description
The company was co-founded by Wang Ke, Wu Di, and Dr. Liu Wenbo. Wang Ke, a graduate of Peking University's Health Science Center, has extensive clinical and business experience. Wu Di, an alumnus of Xi'an Jiaotong University Health Science Center, previously worked at Capital Medical University Xuanwu Hospital. Dr. Liu Wenbo holds a Ph.D. from Tsinghua University's School of Medicine and has deep expertise in neurosurgical navigation systems. Their journey began in 2005 when Wu Di and Wang Ke founded Beijing Huake Hengsheng Medical Technology to develop and produce medical electrodes for neurosurgery. Recognizing the limitations in the market, they decided to develop surgical robots, initiating research and development with Tsinghua University in 2011, which led to the formation of Sinovation Medical.
Sinovation Medical operates on a business model that combines the sale of high-end medical equipment with associated high-value consumables and technical services. Its clients are primarily hospitals and medical institutions, with its products used in over 250 hospitals across China. The firm has established a significant market presence, with its intracranial electrodes and neurosurgical robots holding a leading share in the domestic market. The business has expanded globally, notably after receiving FDA approval for its Sinobot X1, paving the way for international sales.
The company's product portfolio is organized into six main lines: the SR series of neurosurgical robots, the Q300 series of miniature neurosurgical robots, the NS series of neurosurgical navigation systems, the X1000 series for brain and spinal surgery, the LS series of MRI-guided laser ablation therapy systems, and a comprehensive range of intracranial electrodes through its subsidiary, Huake Hengsheng. A key product, the Sinobot X1, is the first neurosurgical robot from a Chinese company to receive FDA clearance in the United States. Another significant offering is the Laser Interstitial Thermal Therapy (LITT) system, the first domestically developed system of its kind in China for treating brain tumors and epilepsy. The company's robots integrate advanced features like 3D structured light for markerless registration, enhancing surgical precision and efficiency.
At a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- China
- Employees
- 23
- Open positions
- None listed
- Dealroom signal
- 47.7/100
- Industry
- Health, Robotics
- Sub-industry
- Health Platform
- Sector
- Health Tech & Medtech, Surgery, Core AI, Medical Robots, Surgical Equipment, Collaborative Robots, Surgical Robots, Hard Tech, AI Applications, DT and LS, science-based
- Business model
- Manufacturing
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Jul 2023 | $14M | $206M | Rongquan Capital · Mizuki Investment · Huiyu Investment · DNV capital | ↗ |
| SERIES DOther financing | Dec 2022 | $41M | $165M | Green River Delta · Denuo Capital Group · Kaifeng Venture Capital · Rongquan Capital | ↗ |
Growth signals
Latest recorded traffic for Sinovation / 华科精准 is 1.3K monthly website visits, down 27.8% over the last three months. Sinovation / 华科精准's team grew 4.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Cowin Venture
Pins Medical
Series B and later9 investors entered at this stage
Green River Delta
- DGDenuo Capital Group
- KCKaifeng Venture Capital
- RCRongquan Capital
- MIMizuki Investment
- HIHuiyu Investment
DNV capital- CKCinda Kunpeng
- JEJunshan Private Equity
Other known investors1 additional known investor
NLVC
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sinovation / 华科精准 on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sinovation / 华科精准’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







